SIR 2024
Renal and GU Interventions
Marios Platon Dimopoulos, MD,MSc
Resident
University Hospital of Patras, Greece
Disclosure information not submitted.
fotis Anagnostopoulos, MD
Interventional Radiology Fellow
2nd Department of Radiology, University General Hospital "ATTIKON" Medical School, National and Kapodistrian University of Athens, Greece
Disclosure information not submitted.
Vasiliki Taki, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Nikos Giannikas, MD, MS
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
George Kolettis, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Christos Papageorgiou, MD
Attending
General University Hospital of Patras, Greece
Disclosure information not submitted.
Michalis Theofanis, MD
Attending Radiologist
General University Hospital of Patras, Greece
Disclosure information not submitted.
Ioannis Spyridonidis, MD, PhD
Attending Radiologist
General University Hospital of Patras, Greece
Disclosure information not submitted.
Georgia Andriana Georgopoulou, MD
Resident
General University Hospital of Patras, Greece
Disclosure information not submitted.
Evaggelos Papachristou, MD, PhD
Professor
General University Hospital of Patras, Greece
Disclosure information not submitted.
Konstantinos Katsanos, MD, PhD, MS
Ass Professor
General University Hospital of Patras, Greece
Disclosure information not submitted.
Dimitrios Karnabatidis, MD, PhD, EBIR, FCIRSE
Professor in Interventional Radiology
Interventional Radiology, Patras University Hospital, Greece
Disclosure information not submitted.
Panagiotis Kitrou, MD, PhD
Asst. Prof. in Interventional Radiology
Patras University Hospital, Greece
Disclosure information not submitted.
To evaluate the safety and effectiveness of the use of covered stents for the treatment of the dysfunctional vascular access.
Materials and Methods:
From July 2006 to December 2022 (16.5 years), 356 patients (65.4 years) with 373 vascular accesses (VA) [72 arteriovenous fistulas (AVFs) and 301 arteriovenous grafts (AVG), age: 2.43 years] underwent 621 procedures with covered stent placement. 258 VA were placed in the left arm and 334 VA in the upper arm. All types of treatments areas and lesion types were included. Primary outcome measures were target lesion primary patency (TLPP) and access circuit survival (ACS), defined as the time between treatment and vascular access thrombosis, surgical intervention, or abandonment. Subgroup analysis on different treatment areas and factors was also perform to identify potential independent predictors that could influence the primary outcome measures.
Results:
Mean follow-up was 1.55 years. TLPP was 60.7%, 38.9% and 21.2% at 6, 12, and 24 months. There was no significant difference between AVFs and AVGs in median TLPP (203 vs 271; p=0.85). ACS was 69.6%, 53% and 34% at 6, 12 and 24 months. There was no significant difference in median ACS between AVFs and AVGs (352 vs 404; p=0.38)and in TLPP (p=0.098) between de novo and restenotic lesions. De novo lesions had better TLPP and ACS compared to restenotic ones (303 vs 216; p=0.068) and (p=0.009) respectively. Infection rate was 2,7% (10/373 accesses).
Conclusion:
In this retrospective analysis covered stents provided results comparable to the literature regarding both TLPP and ACS. Further subgroup analysis findings will also be presented.